GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Debt-to-Asset

Advagene Biopharma Co (ROCO:6709) Debt-to-Asset : 0.02 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Debt-to-Asset?

Advagene Biopharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$1.63 Mil. Advagene Biopharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$0.00 Mil. Advagene Biopharma Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was NT$93.90 Mil. Advagene Biopharma Co's debt to asset for the quarter that ended in Jun. 2023 was 0.02.


Advagene Biopharma Co Debt-to-Asset Historical Data

The historical data trend for Advagene Biopharma Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Debt-to-Asset Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial - 0.02 0.02 0.02 0.01

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.01

Competitive Comparison of Advagene Biopharma Co's Debt-to-Asset

For the Biotechnology subindustry, Advagene Biopharma Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advagene Biopharma Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Advagene Biopharma Co's Debt-to-Asset falls into.



Advagene Biopharma Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Advagene Biopharma Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Advagene Biopharma Co's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advagene Biopharma Co  (ROCO:6709) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Advagene Biopharma Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Advagene Biopharma Co (ROCO:6709) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines